MESOBLAST LTD
MESOBLAST LTD is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain on July 15, 2027. There are 2 upcoming events on record.
Cash runway is approximately 25.7 months based on the most recent reported cash position and quarterly operating burn as of 2025-12-31.
Across 13 concluded trials, 92% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| July 15, 2027 | Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain | Trial Milestone | Phase 3 |
| February 28, 2028 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease | Trial Milestone | Phase 3 |
Track MESO alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open MESO in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.